All Stories

  1. From Listing to Recovery: A Review of Nutritional Status Assessment and Management in Liver Transplant Patients
  2. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
  3. A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma
  4. Individual and population screening of varices needing treatment by a simple, safe and accurate test
  5. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis
  6. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
  7. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients
  8. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
  9. Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives
  10. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
  11. Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies
  12. Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation
  13. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
  14. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease
  15. Comparison of screening strategies with two new tests to score and diagnose varices needing treatment
  16. A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
  17. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  18. Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy
  19. Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)
  20. Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival
  21. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis
  22. Determinants of weight, psychological status, food contemplation and lifestyle changes in patients with obesity during the COVID-19 lockdown: a nationwide survey using multiple correspondence analysis
  23. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  24. Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy
  25. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients
  26. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients
  27. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
  28. Intestinal failure associated liver disease after weaning off home parenteral nutrition: a 12-month follow up
  29. Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
  30. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment
  31. Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice
  32. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges
  33. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
  34. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
  35. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
  36. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
  37. The role of liver and spleen elastography in advanced chronic liver disease
  38. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
  39. Pattern of macrovascular invasion in hepatocellular carcinoma
  40. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease
  41. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
  42. Liver Measurement Stiffness Can Predict Chemotherapy-related Liver Injury and Complications after Surgery for Liver Metastases
  43. Liver and Spleen Stiffness in Vascular Liver Disease
  44. The changing scenario of hepatocellular carcinoma in Italy: an update
  45. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
  46. Malnutrition in hospitalized patients with SARS-CoV-2 infection
  47. Transition of patients with chronic intestinal failure from paediatric to adult center
  48. Clinical impact of sarcopenia assessment in patients with liver cirrhosis
  49. Monofocal hepatocellular carcinoma: How much does size matter?
  50. Reply to: “Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma”
  51. Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?
  52. UEG Week 2020 Poster Presentations
  53. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma
  54. Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
  55. Reply to: “Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma”
  56. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
  57. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study
  58. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments
  59. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk
  60. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients
  61. Non-invasive tests for the prediction of primary hepatocellular carcinoma
  62. Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly
  63. Predictive factors for hepatocellular carcinoma recurrence after curative treatments
  64. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients
  65. Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection
  66. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
  67. Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
  68. Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient
  69. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C
  70. A novel spleen‐dedicated stiffness measurement by FibroScan® improves the screening of high‐risk oesophageal varices
  71. Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance
  72. IDDF2019-ABS-0108 Hepatic decompensation risk is reduced, but not eliminated after direct-acting antivirals: the role of spleen stiffness measurement
  73. Longitudinal evaluation of liver stiffness in three pediatric patients with veno‐occlusive disease
  74. Editorial: collagen proportionate area as a prognostic indicator in NAFLD
  75. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study
  76. Reply to correspondence concerning: “Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection”
  77. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review
  78. “Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?”
  79. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection
  80. Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients
  81. Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome
  82. Prediction of posthepatectomy liver failure: Role of SSM and LSPS
  83. Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study
  84. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients
  85. How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests
  86. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals
  87. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease
  88. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
  89. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
  90. Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808]
  91. Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals
  92. Pancreatic ultrasound elastography and its clinical use in predicting the risk of pancreatic fistulas after pancreatic resection
  93. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study
  94. A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond
  95. Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
  96. Correction to: Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  97. PC.01.2 A SPLEEN STIFFNESS MEASUREMENT-BASED MODEL FOR THE RECOGNITION OF HIGH RISK VARICES: BAVENO VI CRITERIA AND BEYOND
  98. P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C
  99. A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond
  100. IL28 polymorphism and HCC after DAAs for chronic hepatitis C
  101. Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease
  102. Spleen Stiffness by Ultrasound Elastography
  103. Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  104. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study
  105. DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods
  106. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients
  107. Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens
  108. The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients
  109. DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods
  110. The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients
  111. Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens
  112. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients
  113. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT
  114. Gut Microbiota and Celiac Disease